Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$15.11M+1033.76%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martin Zügel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
- Beta
- 1.59
- Country
- CH
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.88
Financials
Revenue
$15.11M+1033.8%Net Income
$1.87MEBITDA
$1.94MFree Cash Flow
$0.00-100.0%EPS (diluted)
$0.02Shares Outstanding (diluted)
98.67M+99.2%Operating Expenses
$14.02MCash & Debt
$75.36MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.57M | $-70.45M | $-0.70 |
| 2024 | $27.31M | $-50.92M | $-0.51 |
| 2023 | $14.80M | $-54.23M | $-0.64 |
| 2022 | $3.94M | $-70.75M | $-0.85 |
| 2021 | $0.00 | $-73.00M | $-0.97 |
| 2020 | $15.43M | $-61.92M | $-0.86 |
| 2019 | $110.46M | $45.44M | $0.64 |
| 2018 | $7.19M | $-50.95M | $-0.82 |
| 2017 | $20.25M | $-26.41M | $-0.46 |
| 2016 | $23.21M | $-7.10M | $-0.14 |
| 2015 | $39.09M | $20.27M | $0.37 |
| 2014 | $30.27M | $10.74M | $0.19 |
| 2013 | $8.64M | $-11.24M | $-0.28 |
Valuation
ACIUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newszacks.com·6d ago·Positive
Best Momentum Stock to Buy for September 30th SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.
View source ↗ - Newsmarketbeat.com·9d ago·Neutral
AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.22 per share
Typical surprise +5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.03 vs $-0.10beat
- Thu, Apr 30$-0.19 vs $-0.20beat
- Fri, Mar 13$-0.18 vs $-0.19beat
- Tue, Nov 4$-0.20 vs $-0.22beat
- Tue, Aug 5$-0.25 vs $-0.20miss
- Wed, Apr 30$-0.21 vs $-0.22beat
Estimates and results for ACIU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACIU officers and directors.
- Bought
- $31k
- Sold
- $59k
1 trade
2 trades
- Pfeifer Andreasold
- Pfeifer Andreasold
- Pfeifer Andreabought
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACIU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.